Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia

55 Páginas.

Autores:: Galindo Orrego, Pablo

Tipo de recurso:

Fecha de publicación:: 2012

Institución:: Universidad de la Sabana

Repositorio:: Repositorio Universidad de la Sabana

Idioma:: spa

id	REPOUSABA2_f2e8c2690a4413b6450fd05944710a07
oai_identifier_str	oai:intellectum.unisabana.edu.co:10818/3952
network_acronym_str	REPOUSABA2
network_name_str	Repositorio Universidad de la Sabana
repository_id_str
dc.title.es_CO.fl_str_mv	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
title	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
spellingShingle	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia Sida-Investigaciones-Colombia VIH-Investigaciones-Colombia
title_short	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
title_full	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
title_fullStr	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
title_full_unstemmed	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
title_sort	Resistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-Colombia
dc.creator.fl_str_mv	Galindo Orrego, Pablo
dc.contributor.advisor.none.fl_str_mv	Galindo Quintero, Jaime Martínez Cajas, Jorge
dc.contributor.author.none.fl_str_mv	Galindo Orrego, Pablo
dc.subject.es_CO.fl_str_mv	Sida-Investigaciones-Colombia VIH-Investigaciones-Colombia
topic	Sida-Investigaciones-Colombia VIH-Investigaciones-Colombia
description	55 Páginas.
publishDate	2012
dc.date.accessioned.none.fl_str_mv	2012-11-14T19:17:11Z
dc.date.available.none.fl_str_mv	2012-11-14T19:17:11Z
dc.date.created.none.fl_str_mv	2012
dc.date.issued.none.fl_str_mv	2012-11-14
dc.type.none.fl_str_mv	bachelorThesis
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.none.fl_str_mv	Tesis de especialización
dc.type.hasVersion.none.fl_str_mv	publishedVersion
dc.identifier.citation.none.fl_str_mv	WHO. Status of the Global HIV epidemic at http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp29_62_en.pdf. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17- 26. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 10, 2011. The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Masquelier B, Lemoigne E, Pellegrin I, Douard D, Sandler B, Fleury HJ. Primary infection with zidovudine-resistant HIV. N Engl J Med 329(15):1123–1124 (1993). David A.M.C. van de Vijver, Annemarie M.J. Wensing, Charles A.B. Boucher, Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, the Netherland. The Epidemiology of Transmission of Drug Resistant HIV-1, 2008. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203-1212. Wensing AM, Van De Vijver D, Asjo B. Analysis from more than 1600 newly diagnosed patients with HIV from 17 european countries shows that 10% of the patients carry primary drug-resistance: The Catch Study. 2nd International AIDS Society Conference on HIV pathogenesis and treatment; Paris July 13-16, 2003; Abstract lb1. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9. Toni T, Masquelier B, Bonard D et al. Primary HIV-1 drug resista Petroni A, Deluchi G, Pryluka D et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 42(4):506–510 (2006). Truong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197 (2006). Rodrigues R, Scherer LC, Oliveira CM et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 116(1–2):201-207 (2006). Brindeiro RM, Diaz RS, Sabino EC et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17(7):1063– 1069 (2003). Lama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42(4):501–505 (2006). Frentz, Dineke, Boucher, Charles A. B. and van de Vijver, David A. M. C. (2012), "Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the World", AIDS Reviews Truong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197 (2006). Lama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42(4):501–505 (2006). DiazGranados, C. Mantilla, W.Lenis, W. n Antiretroviral drug resistance in HIV-infected patients in Colombia. International Journal of Infectious Diseases 2010;14:e298–e303. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May;4(2):65-72 Oette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41(5):573–581 (2006). Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189(12):2174–2180 (2004). Novak RM, Chen L, MacArthur RD et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 40(3):468–474 (2005) Jayaraman GC, Archibald CP, Kim J et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42(1):86–90 (2006). Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell SL, Frost SD, Haubrich RH. PLoS One. 2011;6(6):e21189. Epub 2011 Jun 20. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load Palella FJ, Jr., Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009;151:73-84 Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004;38:723-30. Barbour, JD, Hecht, FM, Wrin, T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683. Weinstock, HS, Zaidi, et al. The epidemiology of antiretroviral drug resistance among drugnaive HIV-1 infected person in 10 US cities. J Infect Dis 2004; 189:2174 Tommy F. Liu and Robert W. Shafer. Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. CID 2006:42 (1 June). Antonella Cingolania, Antinorib, Rizzoa, Murria, Ammassaria, Baldinia, Di Giambenedettoa, Caudaa and De Lucaa. Usefulness of monitoring HIV drug resistance and Adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002, 16:369±379. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2):181–188 (2002). Harzic M, Pellegrin I, Deveau C et al. Genotypic drug resistance during HIV-1 primary infection in France (1996–1999): frequency and response to treatment. AIDS 16(5):793-796 (2002). Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296(7):827–843 (2006). Vandamme AM, Sonnerborg A, it-Khaled M et al. Updated European recommendations for theclinical use of HIV drug resistance testing. Antivir Ther 9(6):829–848 (2004). Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatmentnaive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316- 1323. Martin S. Hirsch, Gunthard, Schapiro, Brun-Vezinet, Clotet, Hammer, Johnson, Kuritzkes, Mellors, Pillay,Yeni, Jacobsen, and Richman. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel. CID 2008:47 (15 July) Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer. Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. Journal of Infectious Diseases, 2009 Aug 1;200(3):453-463 Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. (2010) Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. PLoS ONE 5(12): e15510. doi:10.1371/journal.pone.0015510. Bennet DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009: 4(3);1-8. e4724 Victoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD, PhD, Huldrych F. Günthard, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan M. Schapiro, MD, and Douglas D. Richman, MD. Update of the Drug Resistance Mutations in HIV-1: December 2010. International AIDS Society–USA, Volume 18 Issue 5 December 2010. Cohen et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy N Engl J Med. 2011; 365: 493-505. http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011- Documentoconsenso-TAR-adulto-verordenador.pdf http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-Spanish-5-4.pdf Ocfemia C B, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug resistance-associated mutations by duration of infection among persons newly diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. Infections; March 5-8, 2012; Seattle, Washington. Clinical Care Options. Guía de práctica clínica de VIH/SIDA. Recomendaciones basadas en la evidencia, Colombia. Asociación Colombiana de Infectología, vol. 10 - 4, 2006. http://summaries.cochrane.org/CD006495/antiretroviral-resistance-testing-in-treatment-naivehiv-infected-adults.
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10818/3952
dc.identifier.local.none.fl_str_mv	157927 TE05622
identifier_str_mv	WHO. Status of the Global HIV epidemic at http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp29_62_en.pdf. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17- 26. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 10, 2011. The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Masquelier B, Lemoigne E, Pellegrin I, Douard D, Sandler B, Fleury HJ. Primary infection with zidovudine-resistant HIV. N Engl J Med 329(15):1123–1124 (1993). David A.M.C. van de Vijver, Annemarie M.J. Wensing, Charles A.B. Boucher, Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, the Netherland. The Epidemiology of Transmission of Drug Resistant HIV-1, 2008. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203-1212. Wensing AM, Van De Vijver D, Asjo B. Analysis from more than 1600 newly diagnosed patients with HIV from 17 european countries shows that 10% of the patients carry primary drug-resistance: The Catch Study. 2nd International AIDS Society Conference on HIV pathogenesis and treatment; Paris July 13-16, 2003; Abstract lb1. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9. Toni T, Masquelier B, Bonard D et al. Primary HIV-1 drug resista Petroni A, Deluchi G, Pryluka D et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 42(4):506–510 (2006). Truong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197 (2006). Rodrigues R, Scherer LC, Oliveira CM et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 116(1–2):201-207 (2006). Brindeiro RM, Diaz RS, Sabino EC et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17(7):1063– 1069 (2003). Lama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42(4):501–505 (2006). Frentz, Dineke, Boucher, Charles A. B. and van de Vijver, David A. M. C. (2012), "Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the World", AIDS Reviews DiazGranados, C. Mantilla, W.Lenis, W. n Antiretroviral drug resistance in HIV-infected patients in Colombia. International Journal of Infectious Diseases 2010;14:e298–e303. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May;4(2):65-72 Oette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41(5):573–581 (2006). Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189(12):2174–2180 (2004). Novak RM, Chen L, MacArthur RD et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 40(3):468–474 (2005) Jayaraman GC, Archibald CP, Kim J et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42(1):86–90 (2006). Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell SL, Frost SD, Haubrich RH. PLoS One. 2011;6(6):e21189. Epub 2011 Jun 20. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load Palella FJ, Jr., Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009;151:73-84 Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004;38:723-30. Barbour, JD, Hecht, FM, Wrin, T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683. Weinstock, HS, Zaidi, et al. The epidemiology of antiretroviral drug resistance among drugnaive HIV-1 infected person in 10 US cities. J Infect Dis 2004; 189:2174 Tommy F. Liu and Robert W. Shafer. Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. CID 2006:42 (1 June). Antonella Cingolania, Antinorib, Rizzoa, Murria, Ammassaria, Baldinia, Di Giambenedettoa, Caudaa and De Lucaa. Usefulness of monitoring HIV drug resistance and Adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002, 16:369±379. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2):181–188 (2002). Harzic M, Pellegrin I, Deveau C et al. Genotypic drug resistance during HIV-1 primary infection in France (1996–1999): frequency and response to treatment. AIDS 16(5):793-796 (2002). Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296(7):827–843 (2006). Vandamme AM, Sonnerborg A, it-Khaled M et al. Updated European recommendations for theclinical use of HIV drug resistance testing. Antivir Ther 9(6):829–848 (2004). Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatmentnaive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316- 1323. Martin S. Hirsch, Gunthard, Schapiro, Brun-Vezinet, Clotet, Hammer, Johnson, Kuritzkes, Mellors, Pillay,Yeni, Jacobsen, and Richman. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel. CID 2008:47 (15 July) Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer. Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. Journal of Infectious Diseases, 2009 Aug 1;200(3):453-463 Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. (2010) Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. PLoS ONE 5(12): e15510. doi:10.1371/journal.pone.0015510. Bennet DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009: 4(3);1-8. e4724 Victoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD, PhD, Huldrych F. Günthard, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan M. Schapiro, MD, and Douglas D. Richman, MD. Update of the Drug Resistance Mutations in HIV-1: December 2010. International AIDS Society–USA, Volume 18 Issue 5 December 2010. Cohen et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy N Engl J Med. 2011; 365: 493-505. Ocfemia C B, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug resistance-associated mutations by duration of infection among persons newly diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. Infections; March 5-8, 2012; Seattle, Washington. Clinical Care Options. Guía de práctica clínica de VIH/SIDA. Recomendaciones basadas en la evidencia, Colombia. Asociación Colombiana de Infectología, vol. 10 - 4, 2006. 157927 TE05622
url	http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011- Documentoconsenso-TAR-adulto-verordenador.pdf http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-Spanish-5-4.pdf http://summaries.cochrane.org/CD006495/antiretroviral-resistance-testing-in-treatment-naivehiv-infected-adults. http://hdl.handle.net/10818/3952
dc.language.iso.es_CO.fl_str_mv	spa
language	spa
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	http://purl.org/coar/access_right/c_abf2
dc.publisher.none.fl_str_mv	Universidad de La Sabana
dc.publisher.program.none.fl_str_mv	Especialización en Medicina Interna
dc.publisher.department.none.fl_str_mv	Facultad de Medicina
publisher.none.fl_str_mv	Universidad de La Sabana
dc.source.none.fl_str_mv	Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana
institution	Universidad de la Sabana
bitstream.url.fl_str_mv	https://intellectum.unisabana.edu.co/bitstream/10818/3952/2/license.txt https://intellectum.unisabana.edu.co/bitstream/10818/3952/1/Pablo%20Galindo%20Orrego.pdf https://intellectum.unisabana.edu.co/bitstream/10818/3952/3/Pablo%20Galindo%20Orrego.pdf.txt
bitstream.checksum.fl_str_mv	f52a2cfd4df262e08e9b300d62c85cab 206f7128549107d0138f4c54b5b7bf8d 2680fee47b1e5b820b9e6a796b783913
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5
repository.name.fl_str_mv	Intellectum Universidad de la Sabana
repository.mail.fl_str_mv	contactointellectum@unisabana.edu.co
_version_	1811952226600484864
spelling	Galindo Quintero, JaimeMartínez Cajas, JorgeGalindo Orrego, PabloEspecialista en Medicina Interna2012-11-14T19:17:11Z2012-11-14T19:17:11Z20122012-11-14WHO. Status of the Global HIV epidemic at http://data.unaids.org/pub/GlobalReport/2008/jc1510_2008_global_report_pp29_62_en.pdf.Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17- 26.Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents January 10, 2011. The DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC).Masquelier B, Lemoigne E, Pellegrin I, Douard D, Sandler B, Fleury HJ. Primary infection with zidovudine-resistant HIV. N Engl J Med 329(15):1123–1124 (1993).David A.M.C. van de Vijver, Annemarie M.J. Wensing, Charles A.B. Boucher, Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, the Netherland. The Epidemiology of Transmission of Drug Resistant HIV-1, 2008.Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394.Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203-1212.Wensing AM, Van De Vijver D, Asjo B. Analysis from more than 1600 newly diagnosed patients with HIV from 17 european countries shows that 10% of the patients carry primary drug-resistance: The Catch Study. 2nd International AIDS Society Conference on HIV pathogenesis and treatment; Paris July 13-16, 2003; Abstract lb1.Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9.Toni T, Masquelier B, Bonard D et al. Primary HIV-1 drug resistaPetroni A, Deluchi G, Pryluka D et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 42(4):506–510 (2006).Truong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197 (2006).Rodrigues R, Scherer LC, Oliveira CM et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 116(1–2):201-207 (2006).Brindeiro RM, Diaz RS, Sabino EC et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17(7):1063– 1069 (2003).Lama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42(4):501–505 (2006).Frentz, Dineke, Boucher, Charles A. B. and van de Vijver, David A. M. C. (2012), "Temporal Changes in the Epidemiology of Transmission of Drug-Resistant HIV-1 across the World", AIDS ReviewsTruong HH, Grant RM, McFarland W et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20(17):2193–2197 (2006).Lama JR, Sanchez J, Suarez L et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 42(4):501–505 (2006).DiazGranados, C. Mantilla, W.Lenis, W. n Antiretroviral drug resistance in HIV-infected patients in Colombia. International Journal of Infectious Diseases 2010;14:e298–e303.Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870.Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May;4(2):65-72Oette M, Kaiser R, Daumer M et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41(5):573–581 (2006).Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189(12):2174–2180 (2004).Novak RM, Chen L, MacArthur RD et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 40(3):468–474 (2005)Jayaraman GC, Archibald CP, Kim J et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42(1):86–90 (2006).Poon AF, Aldous JL, Mathews WC, Kitahata M, Kahn JS, Saag MS, Rodríguez B, Boswell SL, Frost SD, Haubrich RH. PLoS One. 2011;6(6):e21189. Epub 2011 Jun 20. Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadPalella FJ, Jr., Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med 2009;151:73-84Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004;38:723-30.Barbour, JD, Hecht, FM, Wrin, T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683.Weinstock, HS, Zaidi, et al. The epidemiology of antiretroviral drug resistance among drugnaive HIV-1 infected person in 10 US cities. J Infect Dis 2004; 189:2174Tommy F. Liu and Robert W. Shafer. Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. CID 2006:42 (1 June).Antonella Cingolania, Antinorib, Rizzoa, Murria, Ammassaria, Baldinia, Di Giambenedettoa, Caudaa and De Lucaa. Usefulness of monitoring HIV drug resistance and Adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002, 16:369±379.Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2):181–188 (2002).Harzic M, Pellegrin I, Deveau C et al. Genotypic drug resistance during HIV-1 primary infection in France (1996–1999): frequency and response to treatment. AIDS 16(5):793-796 (2002).Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296(7):827–843 (2006).Vandamme AM, Sonnerborg A, it-Khaled M et al. Updated European recommendations for theclinical use of HIV drug resistance testing. Antivir Ther 9(6):829–848 (2004).Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatmentnaive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316- 1323.Martin S. Hirsch, Gunthard, Schapiro, Brun-Vezinet, Clotet, Hammer, Johnson, Kuritzkes, Mellors, Pillay,Yeni, Jacobsen, and Richman. Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel. CID 2008:47 (15 July)Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer. Predictive Value of HIV-1 Genotypic Resistance Test Interpretation Algorithms. Journal of Infectious Diseases, 2009 Aug 1;200(3):453-463Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, et al. (2010) Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009. PLoS ONE 5(12): e15510. doi:10.1371/journal.pone.0015510.Bennet DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009: 4(3);1-8. e4724Victoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD, PhD, Huldrych F. Günthard, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan M. Schapiro, MD, and Douglas D. Richman, MD. Update of the Drug Resistance Mutations in HIV-1: December 2010. International AIDS Society–USA, Volume 18 Issue 5 December 2010.Cohen et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy N Engl J Med. 2011; 365: 493-505.http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011- Documentoconsenso-TAR-adulto-verordenador.pdfhttp://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-Spanish-5-4.pdfOcfemia C B, Kim D, Ziebell R, et al. Prevalence and trends of transmitted drug resistance-associated mutations by duration of infection among persons newly diagnosed with HIV-1 infection: 5 states and 3 municipalities, US, 2006 to 2009. Infections; March 5-8, 2012; Seattle, Washington. Clinical Care Options.Guía de práctica clínica de VIH/SIDA. Recomendaciones basadas en la evidencia, Colombia. Asociación Colombiana de Infectología, vol. 10 - 4, 2006.http://summaries.cochrane.org/CD006495/antiretroviral-resistance-testing-in-treatment-naivehiv-infected-adults.http://hdl.handle.net/10818/3952157927TE0562255 Páginas.Se realizo un estudio para determinar la frecuencias de resistencias trasmitidas del HIV in pacientes atendidos en la Corporación de Lucha contra el SIDA en Cali, Colombia. Se incluyeron pacientes con infección por VIH confirmada nunca expuestos a tratamiento antirretroviral y que tuvieran estudio genotípico de resistencia en el periodo del 2008 al 2010. Adicionalmente fueron incluidos en el análisis factores socio-demográficos y condiciones relacionadas con el VIH. 152 pacientes fueron incluidos, la frecuencia de resistencia primaria fue del 13.2%. Para NNRTI se encontró mutaciones de resistencia en 5.3%, para NRTI en 4.6% y para IP en 2.0%. La frecuencia de resistencia primaria en este estudio es más alta a la encontrada en estudios previos en Colombia y similar a la de otros países con mayor uso de antirretrovirales.spaUniversidad de La SabanaEspecialización en Medicina InternaFacultad de MedicinaUniversidad de La SabanaIntellectum Repositorio Universidad de La SabanaSida-Investigaciones-ColombiaVIH-Investigaciones-ColombiaResistencias del VIH por genotipificación y características asociadas, en pacientes sin exposición previa a tratamiento antirretroviral-tar (naïve o “vígenes” a tratamiento), bajo atención integral especializada de la corporación de lucha contra el sida en el periodo comprendiendo entre enero de 2008 y diciembre de 2010, Cali-ColombiabachelorThesisTesis de especializaciónpublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/access_right/c_abf2LICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://intellectum.unisabana.edu.co/bitstream/10818/3952/2/license.txtf52a2cfd4df262e08e9b300d62c85cabMD52ORIGINALPablo Galindo Orrego.pdfPablo Galindo Orrego.pdfVer documento en PDFapplication/pdf503568https://intellectum.unisabana.edu.co/bitstream/10818/3952/1/Pablo%20Galindo%20Orrego.pdf206f7128549107d0138f4c54b5b7bf8dMD51TEXTPablo Galindo Orrego.pdf.txtPablo Galindo Orrego.pdf.txtExtracted Texttext/plain132936https://intellectum.unisabana.edu.co/bitstream/10818/3952/3/Pablo%20Galindo%20Orrego.pdf.txt2680fee47b1e5b820b9e6a796b783913MD5310818/3952oai:intellectum.unisabana.edu.co:10818/39522019-08-13 16:11:05.388Intellectum Universidad de la Sabanacontactointellectum@unisabana.edu.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

Publicaciones similares